Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Who Require Opioid Analgesia for Acute Moderate to Severe Pain

Inclusion Criteria include: * Must have written informed consent provided by the parent or legal guardian and/or patient assent, when appropriate * Male and female children, from birth to aged 6 years, inclusive, with minimum weight of 2.5 kg * Have or are anticipated to have acute moderate to severe pain; requiring treatment with an intravenous (IV) opioid analgesic medication for at least 24 hours postoperatively or; due to prolonged endotracheal intubation requiring IV opioid analgesic treatment for at least 24 hours poststabilization * Must have stable vital signs * Must have stable respiratory status * Must be inpatient for the treatment period of the study Exclusion Criteria include: * Have any known allergy or sensitivity to buprenorphine or other opioids (this criterion does not include patients who have experienced common opioid side effects \[eg, nausea, constipation\]) * Have evidence of impaired renal function * Have hepatic impairment * Have history of seizures * Have a history of sleep apnea within the past year * Have structural heart disease or a pacemaker * Have clinically unstable cardiac disease * Have used any investigational medication/therapy within 30 days prior to the first dose of study drug * Are deemed to be unsuitable by the investigator for reason(s) not specifically stated in the exclusion criteria. Other protocol-specific inclusion/exclusion criteria may apply.